Search

Displaying results 2701 - 2710 of 10000 in total
  1. Drug

    Quinupristin

    go.drugbank.com/drugs/DB01369
    Approved

    The combination of the two components acts synergistically and is more effective in vitro than each component alone. … Dalfopristin inhibits the early phase of protein synthesis in the bacterial ribosome and quinupristin inhibits the late phase of protein synthesis.

  2. Drug

    Fluvastatin

    go.drugbank.com/drugs/DB01095
    ApprovedInvestigational

    HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. … It is also the first entirely synthetic HMG-CoA reductase inhibitor and is structurally distinct from the fungal derivatives of this therapeutic class.

  3. Drug

    Elbasvir

    go.drugbank.com/drugs/DB11574
    Approved

    [A19626] In a computational target-based drug repurposing investigation published in April 2020, elbasvir was predicted to bind stably and preferentially to three proteins necessary for viral replication … HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, affecting 72% of all chronic HCV patients.

  4. Drug

    Dicoumarol

    go.drugbank.com/drugs/DB00266
    Approved

    In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases. … Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K.

  5. Drug

    Gepirone

    go.drugbank.com/drugs/DB12184
    Approved

    Gepirone, an azapirone, is a pharmacologic analog of [buspirone] that acts selectively on the pre- and post-synaptic 5HT<sub>1A</sub> receptors. … It was not until an extended-release formulation of gepirone was made available that gepirone became a potential candidate for a new antidepressant.

  6. Drug

    Rimonabant

    go.drugbank.com/drugs/DB06155
    ApprovedWithdrawn

    It was rejected for approval for use in the United States. … Rimonabant is the first selective CB1 receptor blocker to be approved for use anywhere in the world. Rimonabant is approved in 38 countries including the E.U., Mexico, and Brazil.

  7. Drug

    Pregabalin

    go.drugbank.com/drugs/DB00230
    ApprovedInvestigational

    [L1006,L7066] It may have dependence liability if misused but the risk appears to be highest in patients with current or past substance use disorders.[A31161] … Pregabalin is structurally similar to gamma-aminobutyric acid (GABA) - an inhibitory neurotransmitter.

    Products: PG-LIN 75 (Pregabalin Capsules 75 mg)
  8. Drug

    Famtozinameran

    go.drugbank.com/drugs/DB17088
    ApprovedInvestigational

    The Omicron variant of SARS-CoV-2 is a variant of concern that was first reported in November 2021. … It is administered in combination with [tozinameran] for active immunization against COVID-19 caused by SARS-CoV-2, including infection caused by Omicron BA.4/BA.5.[L43907,L43912]

  9. Drug

    Daridorexant

    go.drugbank.com/drugs/DB15031
    ApprovedInvestigational

    Daridorexant reduces overactive wakefulness: in the investigational trials, daridorexant reportedly improved sleep and daytime functioning in patients with insomnia. … [A244280] Daridorexant was approved by the European Commission on May 3, 2022, as the first dual orexin receptor antagonist approved in the market,[L41725] and by Health Canada on April 26, 2023.

  10. Drug

    Didanosine

    go.drugbank.com/drugs/DB00900
    ApprovedInvestigational

    A dideoxynucleoside compound in which the 3&#39;-hydroxy group on the sugar moiety has been replaced by a hydrogen. … Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative